基石药业-B(02616.HK)全球研发总部及产业化基地项目落户苏州工业园区
格隆汇8月6日丨基石药业-B(02616.HK)公布,公司全球研发总部及产业化基地签约仪式于2019年8月6日正式举行,标志着又一高端高新的研发生产基地落户苏州。苏州工业园区党工委副书记、管委会主任丁立新、党工委委员、管委会副主任、组织部部长林小明,苏州新建元控股集团董事长叶晓敏、总裁亢越,基石药业董事长、执行董事兼首席执行官江宁军博士等领导出席签约仪式。
苏州工业园区对项目建设方案和项目投资给予了极大的支持。根据协议,项目采用代建方式,规划总计容建筑面积近10万㎡,建成后将同时具备生物药和化学药的研发、中试及商业化生产的一体化研发生产能力,设计产能可达2.6万L大分子生物药和10亿片小分子化学药片剂和胶囊。整体项目计划于2020年初破土动工。
公司称,基石药业致力于开发创新肿瘤治疗药物,以肿瘤治疗联合疗法为核心,结合精准治疗,解决中国高发癌症及临床未满足的医疗需求,是中国唯一一家拥有临床阶段PD-1、PD-L1、CTLA-4这三个免疫治疗骨架药物的公司。
目前,基石药业已有5款候选药物正处于或接近关键性临床试验,在未来的1-2年内,该公司将有多款新药产品陆续商业上市。产业化基地的落成,将支援本公司形成“自建+外包”的混合生产模式,两条生产线互为补充,保证产能。研发基地也将进一步加强该公司自主研发的能力,提高研发效率以及拓展合作的空间。同时,基石药业强大的研发能力将能更好地落实国家《“健康中国2030”规划纲要》精神,让更多肿瘤创新药物惠及中国病患,提高全民健康水准。
基石药业董事长、执行董事兼首席执行官江宁军博士表示:近年来,苏州工业园区全力推动战略性新兴产业发展,已经形成了充满创新活力的生物医药产业生态圈。自2016年创立以来,基石药业得到了苏州工业园区的大力支持。此次公司选址苏州作为全球研发总部及产业化基地,也显示了公司对苏州工业园区政策环境和基础设施的充分信心。基石药业将立足苏州,成为全球知名的领先中国生物制药公司,争取为苏州乃至世界生物制药产业做出更大贡献。
基石药业产品开发及制造高级副总裁李景荣博士表示:药品的生产工艺,产品的安全性、药效、品质和供应链,对患者来说至关重要。公司会在整个产品开发和生产流程中合理设计、严谨执行,力争将基石药业全球研发总部及产业化基地打造成国际一流、国内顶尖的医药创新基地,为患者生产价格合理的高品质‘放心药
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.